On September 26, the CME Coalition submitted comments responding to the Food and Drug Administration (FDA) updated draft guidance regarding diversity action plans (DAPs) in clinical studies. This comment opportunity provided a valuable opportunity for the CME Coalition to engage in conversations about the importance of ensuring health equity in medical product development and, ultimately, health care outcomes.
After several meetings of our diligent working group, we developed comments that emphasize the role of CE providers in promoting health equity by ensuring care providers are educated on diversity action plans and outlines how CE helps bridge the gap in trial participation among underrepresented populations through increased collaboration with the FDA.
After several meetings of our diligent working group, we developed comments that emphasize the role of CE providers in promoting health equity by ensuring care providers are educated on diversity action plans and outlines how CE helps bridge the gap in trial participation among underrepresented populations through increased collaboration with the FDA.
| cme_coalition_dap_comment_letter_9.24.24.pdf |
